Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 4/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 9/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15700364 | 0.85 | GRIA1 (0.35) | ITGB1ITGA4ITGB7ARKDM4E | |
| SCHEMBL14818821 | 0.78 | AR (0.37) | ITGB1ITGA4ITGB7KDM5BAR | |
| SCHEMBL22017507 | 0.76 | KDM4E (0.40) | KDM5BKDM4EALDH1A1HPGD | |
| SCHEMBL15648526 | 0.75 | PABPC1 (0.48) | ALDH1A1HPGD | |
| SCHEMBL24437199 | 0.75 | COMT (0.40) | ITGB1ITGA4ITGB7ARKDM4E | |
| SCHEMBL20051737 | 0.75 | AR (0.35) | ITGB1ITGA4ITGB7ARKDM4E | |
| SCHEMBL1689752 | 0.75 | AR (0.35) | ITGB1ITGA4ITGB7ARKDM4E | |
| SCHEMBL22017511 | 0.72 | AR (0.34) | ITGB1ITGA4ITGB7ARKDM4E | |
| SCHEMBL14803746 | 0.72 | ITGB1 (0.36) | ITGB1ITGA4ITGB7KDM5BAR | |
| SCHEMBL20051302 | 0.72 | ITGB1 (0.34) | ITGB1ITGA4ITGB7ARKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB7 2700/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB7 2700/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB7 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.